Poor
Not Aligned
Patient Risk:
High
Summary
Mechanism and general statin-indication concepts are partially supported by the provided label excerpts, but multiple specific interaction and adverse-effect claims involving antihistamines (including named examples) are not supported by the provided FDA label sections and appear potentially misleading.
Category Scores
Accurate Statements
Lipitor belongs to the drug class known as statins.
12.1 Mechanism of Action (HMG-CoA reductase inhibitor; references to 'drugs in this class') and 5.1 Skeletal Muscle (statin class terminology).
Statins (Lipitor) work by inhibiting the production of cholesterol in the liver.
12.1 Mechanism of Action (inhibits HMG-CoA reductase/cholesterol synthesis in the liver).
Unsupported Statements
Taking Lipitor and certain antihistamines together can increase the risk of muscle damage.
The provided label sections describe increased myopathy/rhabdomyolysis risk with specific interacting agents (e.g., cyclosporine, strong CYP3A4 inhibitors), but do not mention antihistamines.
Lipitor can increase the risk of muscle damage, particularly when taken with diphenhydramine (Benadryl).
Diphenhydramine/Benadryl is not mentioned among interacting agents in the provided label excerpts.
Both Lipitor and antihistamines can cause liver damage.
The provided label excerpt attributes liver enzyme abnormalities to statins; it does not state antihistamines cause liver damage.
Taking Lipitor and antihistamines together may increase the risk of liver damage.
No antihistamine combination/liver interaction is described in the provided label excerpts.
Antihistamines such as fexofenadine (Allegra) can increase the risk of bleeding when taken with Lipitor.
The provided label excerpt on bleeding risk discusses warfarin/prothrombin time; fexofenadine/antihistamines are not discussed.
A doctor should be consulted before taking Lipitor and antihistamines together due to potential interactions.
The provided label excerpts give specific interaction guidance for listed interacting agents, but do not include an antihistamine-specific counseling statement.
The combination of statins and antihistamines can increase the risk of adverse effects, including muscle damage and liver damage.
Muscle and liver risk discussions in the provided excerpts do not describe antihistamine combination interactions.
It is not recommended to take Lipitor and antihistamines together without consulting a doctor first.
No antihistamine-specific 'not recommended' statement is present in the provided label excerpts.
Potential interactions between Lipitor and antihistamines include increased risk of muscle damage, liver damage, and bleeding.
The provided interaction/warnings excerpts do not list antihistamines among interacting agents linked to these risks.
It is not recommended to take OTC antihistamines with Lipitor without consulting a doctor first.
The provided label excerpts do not address OTC antihistamines or antihistamines in general.
If adverse effects occur after taking Lipitor and antihistamines together, contact a doctor immediately.
The label excerpt instructs patients to report unexplained muscle symptoms and to discontinue if myopathy is suspected, but does not provide this antihistamine-combination-specific instruction.
Antihistamines are medications used to relieve symptoms of allergies such as itching, sneezing, runny nose, and hives.
Not addressed in the provided Lipitor label sections.
Antihistamines work by blocking the action of histamine.
Not addressed in the provided Lipitor label sections.
Antihistamines can be found over-the-counter (OTC) or by prescription, depending on the severity of the allergy.
Not addressed in the provided Lipitor label sections.
Lipitor is a prescription medication used to lower cholesterol levels in the blood.
The provided indication text supports use as lipid-altering therapy in specified populations, but the excerpt does not explicitly support the exact phrasing ('prescription medication' / 'lower cholesterol levels in the blood').
Lipitor is commonly prescribed to individuals with high cholesterol, heart disease, or those at risk of developing these conditions.
The excerpt supports therapy for patients at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia and mentions CHD/multiple risk factors, but does not support the characterization 'commonly prescribed.'
Contradictions
Important Omissions
No label-supported contraindications, boxed warnings, or specific dosing/administration details were evaluated against the provided excerpts (because none were claimed).
Importance:
Low
Safety Assessment
Potential Patient Risk:
High
Unsubstantiated antihistamine-specific interaction claims (muscle damage, liver damage, bleeding) are not supported by the provided Lipitor label sections and could mislead patients about risk and appropriate precautions.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Multiple specific antihistamine-related drug interaction and adverse-effect claims are not supported by the provided FDA label excerpts for LIPITOR.
Suggested Improvement
Remove antihistamine-specific interaction statements (including named examples like diphenhydramine and fexofenadine) unless supported by the actual FDA label interaction/warnings sections; limit interaction claims to the interacting agents explicitly listed in the provided label (e.g., cyclosporine and certain strong CYP3A4 inhibitors) and to label-supported monitoring/reporting language.